•		0. 4		Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
bstitute for form 1449A/PTO	7	3		COMPLETE IF KNOWN
NFORMATION :	ŊĮS	erosuke g	Application Number	10/579,605
	\\$5.	<i>L</i> F./	Filing Date	May 17, 2006
IAIEWENI DI	Ar		First Named Inventor	Harada et al.
		,	Group Art Unit	1647
(use as many sheets as necessary)			Examiner Name	
1	of	3	Attorney Docket Number	21350YP
	TATEMENT BY	NFORMATION DISTATEMENT BY AF	NFORMATION DISCLOSURE BY TATEMENT BY AFTER STATEMENT BY AFTER STATEMEN	Application Number TATEMENT BY A Filing Date First Named Inventor Group Art Unit Examiner Name

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		2005/0079173		Niehrs et al.	04/14/2005	
		2005/0069915		McCarthy	03/31/2005	
	-	2003/0068312		McCarthy	04/10/2003	
		2003/0181660		Todd et al.	09/25/2003	
		·			,	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Office Number C		Kind Code (known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
			WO 02/092015		Genome Therapeutics Corporation/Wyeth	11/21/2002	
			WO 00/52047		Millennium Pharmaeuticals, Inc.	09/08/2000	
			WO 99/22000		Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts	05/06/1999	
			WO 98/46755		Millennium Biotherapeutics, Inc.	10/22/1998	
			WO 98/46743		The Wellcome Trust Limited as trustee to The Wellcome Trust/Merck & Co., Inc.	10/22/1998	
				-		· · · · · · · · · · · · · · · · · · ·	
REF	RE	MCI	ES CONSIDERED EXC	EP	WHERE LINED THROUG	H. /DG/	

Examiner Signature /Daniel Gamett/ (03/19/2008) Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sut	bstitute for form 1449B/PTO				COMPLETE IF KNOWN
	NFORMATION I	DISCLOS	URE	Application Number	10/579,605
C!	TATEMENT DA	OLP E	42	Filing Date	May 17, 2006
.	STATEMENT BY APPLICANT		<i>5</i> 1	First Named Inventor	Harada et al.
	**	APR 2.0 20	~/	Group Art Unit	1647
	(use as many sheet)	BADENAN	TC2.	Examiner Name	
Sheet	2	of	3	Attorney Docket Number	21350YP
				4	·

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Bafico et al., Nature Cell Biology, Vol. 3 (2001), pp. 683-686, "Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow"
	AB	Bennett et al., J. of Biol. Chem., Vol. 277 (2002), pp. 30998-31004, "Regulation of Wnt signaling during adipogenesis"
	AC	Boyden et al., N. Eng. J. of Med., Vol. 346 (2002), pp. 1513-1521, "High bone density due to a mutation in LDL-receptor-related protein 5"
	AD	Davidson et al,. Development, Vol. 129 (2002), pp. 5587-5596, "Kremen proteins interact with Dickkopf1 to regulate anteroposterior CNS patterning"
	AE	Fujino et al., PNAS, Vol. 100 (2003), pp. 229-234, "Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion"
	AF	Glinka et al., Nature, Vol. 391 (1998), pp. 357-362, "Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction"
	AG	Gong et al., Cell, Vol. 107 (2001), pp. 513-523, "LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development"
	АН	Hey et al., Gene, Vol. 216 (1998), pp. 103-111, "Cloning of a novel member of the low-density lipoprotein receptor family"
	ΑI	Hsu et al., Molecular and Cellular Biol., Vol. 18 (1998), pp. 4807-4818, "Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin"
	AJ	Katagiri et al., J. of Cell Biology, Vol. 127 (1994), pp. 1755-1766, "Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage"
	AK	Kato et al., J. of Cell Biology, Vol. 157 (2002), pp. 303-314, "Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor"
	AL	Krupnik et al., Gene, Vol. 238 (1999), pp. 301-313, "Functional and structural diversity of the human Dickkopf gene family"
	AM	Li et al., The EMBO Journal, Vol. 18 (1999), pp. 4233-4240, "Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1"
	AN	Little et al., Am. J. Hum. Genet., Vol. 70 (2002), pp. 11-19, "A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait"
	AO	Magoori et al, J. of Biol. Chem., Vol. 278 (2003), pp. 11331-11336, "Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related"

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

Examiner Signature	/Daniel Gamett/ (03/19/2008)	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•			
Substitute for form 1449B/PTO			COMPLETE IF KNOWN
INFORMATION DI	SCL OSURE	Application Number	10/579,605
OT A TENANT OF	EW	Filing Date	May 17, 2006
SIAIEMENI BY A	PPLICANI	First Named Inventor	Harada et al.
(APR	20 to 5	Group Art Unit	1647
(use as many sheets as	necessary	Examiner Name	
1 .	2	Attorney Docket Number	21350YP
	INFORMATION DI STATEMENT BY A (use as many snegts as	INFORMATION DISCLOSURE PE APPLICANT (use as many snegts as necessary)	Application Number Filing Date First Named Inventor Group Art Unit Examiner Name

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AP	Mao et al., Gene, Vol. 302 (2003), pp. 179-183, Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling"
	AQ	Mao et al., Molecular Cell, Vol. 7 (2001), pp. 801-809, "Low-density lipoprotein receptor-related protein-5 binds to axin and regulates the canonical Wnt signaling pathway"
	AR	Mao et al., Nature, Vol. 411 (2001), pp. 321-325, "LDL-receptor-related protein 6 is a receptor for Dickkopf proteins"
	AS	Mao et al., Nature, Vol. 410 (2002), pp. 664-667, "Kremen proteins are Dickkopf receptors that regulate Wnt/beta-protein signaling"
	АТ	Patel et al., N. Eng. J. Med., Vol. 346 (2002), pp. 1572-1574, "Regulation of bone formation and vision by LRP5"
	AU	Semenov et al., Current Biology, Vol. 11 (2001), pp. 951-961, "Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6"
	AV	Sjolander et al., Anal. Chem., Vol. 63 (1991), pp. 2338-2345, "Integrated fluid handlding system for biomolecular interaction analysis"
	AW	Szabo et al., Current Opin. in Structural Biol., Vol. 5 (1995), pp. 699-705, "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA)"
	AX	Yuan et al., J. of Biol. Chem., Vol. 274 (1999), pp. 30419-30423, "Suppression of glycogen synthase kinase activity is not sufficient for leukemia enhancer factor-1 activation"
	AY	Yamaguchi et al., Biochem. and Biophys. Res. Comm., Vol. 220 (1996), pp. 366-371, "Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and"
!		
		20, 000 (00° 100, 100, 100, 100, 100, 100, 100, 1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DG/

	Examiner Signature	/Daniel Gamett/ (03/19/2008)	Date Considered	
--	-----------------------	------------------------------	--------------------	--

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.